News

News

Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

10.03.2014

AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.

LinkedIn1Twitter1Facebook0Google+0tumblr

Comments are closed.

FDA expands approved use of Imbruvica for chronic lymphocytic leukemia
ANSM: Stresam® (étifoxine): Modification de l’AMM: libellé d’indication, données de pharmacovigilance et de pharmacodynamie
FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
FDA Guidance for Industry: The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]
EMA: Meeting highlights from the CHMP 21-24 July 2014
European Medicines Agency recommends approval of two new treatment options for rare cancers
EMA: CMDh endorses suspension of methadone oral solutions containing high molecular weight povidone
FDA approves Zydelig for three types of blood cancers
FDA approves new extended-release oxycodone with abuse-deterrent properties
UK MHRA: European review concludes positive benefit risk of emergency contraceptives